Landing
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Beyond the Drip: Elemental IV’s Infrastructure Play for a Fragile Supply Chain
In the high-stakes world of life sciences, we often hunt for the next “miracle molecule” or gene-editing breakthrough. But Storme Paes, Founder and Commercial Director of Elemental IV, found her mission in something far more fundamental, yet dangerously overlooked: a simple bag of saltwater. The “Meeting Room” Revelation The genesis of Elemental IV didn’t occur […]
From Mediocre Portfolios to 18% Returns: EFM’s Radical Transparency in Private Markets
Tired of mediocre returns? Emerging Funds Management (EFM) Founding Partner Surendra Pather explains how his firm fills the bank funding gap for developers while delivering 18% returns to sophisticated investors through a radical, transparent fiduciary model.
Silent Pain and Smart Monitors: The High-Stakes Race to De-Risk the Operating Theatre
Anesthesia has long been considered more “art” than science, leaving clinicians to manage high-stakes sedation with aging tools. Cortical Dynamics is changing the clinical reality with BARM 2.0—an AI-powered monitor that provides real-time visibility into the brain’s response to pain and sedation, backed by a global licence and cooperation agreement with Philips and a decade of R&D.
The $3 Billion Blind Spot: How Venstra Medical is using “Collapsible” Physics to Challenge a Global Med-Tech Giant
In the high-stakes theater of the cath lab, cardiogenic shock is the ultimate emergency. Now, a PhD in fluid mechanics and a frontline cardiologist are deploying a “collapsible” breakthrough to disrupt a 30-year monopoly. The Engineer’s Mission For Dr. Martin Cook, the stakes of medical engineering aren’t measured in blueprints, but in heartbeats. A PhD […]
The Blue-Collar ‘Muscle’ Behind Australia’s $100bn Pipeline: One Key Resources Eyes Expansion
As Australia faces a “perfect storm” of low unemployment and an ambitious $100bn project pipeline, One Key Resources MD Ben Lewis explains why the next five years will be defined by the “muscle power” required to deliver the nation’s energy and infrastructure goals.
Off-the-Shelf, On-the-Money: How a Melbourne Biotech is Expanding its Oncology Platform to Endometriosis
Cartherics is bridging the gap in women’s health by utilising iPSC-derived Natural Killer cells to target both ovarian cancer and endometriosis. With a proprietary manufacturing facility and a lead candidate heading to Phase 1 trials, the company is industrialising cell therapy to solve a multi-billion dollar unmet need.
The Billion-Dollar Blind Spot: The Australian Tech Making ‘Invisible’ Decay a Visible Asset for Investors
Incisive Technologies is moving dentistry from “restorative” to “preventative.” By detecting decay at 30 microns—long before it appears on an X-ray—their FDA-approved BlueCheck tool is eliminating the industry’s “watch and wait” mantra and opening a massive new frontier for clinical and at-home oral health monitoring.
Jevons Paradox: The 160-Year-Old Idea That Explains Why AI Is Creating More Jobs, Not Fewer
When technological efficiency increases the supply of a resource, it paradoxically leads to higher total consumption and expansion of the market. This pattern, known as Jevons Paradox, played out with steam engines, automobiles, and aviation. Today, the same dynamic is happening with artificial intelligence: AI is making software development cheaper and faster, which is unlocking massive, latent demand for new applications and creating a boom in software engineering roles globally. The key question is what new forms of human effort will emerge when the cost of the old ones drops to near zero.
Backed By Leading Investment Groups and Family Offices
